Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05341141
Other study ID # BC-P30(FZQ)
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 10, 2022
Est. completion date November 2026

Study information

Verified date June 2022
Source Peking University
Contact Zhaoqing Fan, MD
Phone +86-10-88197838
Email zhqfan@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multi-center, randomized study designed to evaluate the clinical efficacy of cryotherapy combined with compression therapy in preventing albumin-paclitaxel induced peripheral neuropathy.


Description:

All HER-2 negative breast cancer patients received neoadjuvant chemotherapy with four cycles of dose-dense epirubicin and cyclophosphamide (ddEC) followed by four cycles of dose-dense albumin-paclitaxel (ddT). The patients were randomly assigned in a 1:1 ratio to receive cryotherapy combined with compression or no intervention. The primary endpoint was incidence of grade 3 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0.


Recruitment information / eligibility

Status Recruiting
Enrollment 102
Est. completion date November 2026
Est. primary completion date August 2026
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: 1. Female patients aged from 20 to 70 years old; 2. Histologically confirmed as invasive breast cancer; 3. HER-2 negative (defined by IHC 0 or 1+ ,or FISH negative); 4. Participants who meet any of the following conditions: 1) T > 2 cm, ER<1% and PR<1%; 2) T > 2 cm, ER=1% and biopsy pathology (FNAB or CNB) diagnosed regional lymph node metastasis; 5. Without any previous treatment; 6. ddEC-ddT neoadjuvant chemotherapy is planned; 7. Participants must have at least one measurable disease according to RECIST 1.1; 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 9. LVEF = 50%; 10. The ECG results are judged to be almost normal or normal, or the investigator judges that the abnormalities are not clinically significant; 11. Bone marrow function: absolute neutrophil counts (ANC) = 1.5x10^9/L, platelets = 100x10^9/L, hemoglobin = 90g/L; 12. Liver and kidney function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are both =2.5 ULN; serum total bilirubin and serum creatinine are both = 1.5 ULN; 13. Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form. Exclusion Criteria: 1. Breast cancer with distant metastasis; 2. A history of other malignancies; 3. In the past or present, participants with sensory or motor neurological diseases; 4. Participants who are known to be allergic to the active or other components of the study treatment; 5. Cerebral thrombosis is present; 6. In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate > 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 [Mobitz 2] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) ncontrolled hypertension (eg systolic blood pressure > 180mm Hg or diastolic blood pressure > 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure; 7. Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active pepticulcer, unstable diabetes; 8. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation; 9. Participants who were judged by the investigator to be unsuitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Frozen glove and sock
Preparation of frozen glove and sock: 4? for 3 hours.
Drug:
ddEC-ddT
Epirubicin (E) 90~100mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m^2, i.v., d1, q2w, for 4 cycles.

Locations

Country Name City State
China Peking University Cancer Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University CSPC Ouyi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of grade 3 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0 Incidence of grade 3 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0 4 years
Secondary Incidence of grade 2 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0 Incidence of grade 2 and higher peripheral neuropathy as assessed by NCI-CTCAE V5.0 4 years
Secondary Proportion of patients reporting level D and above based on the Patient Neurotoxicity Questionnaire (PNQ) PNQ scale ranges from scores A to E; with scoring of A being not affected neuropathy, and E with the worst neuropathy. 4 years
Secondary EORTC QLQ-CIPN20 The EORTC QLQ-CIPN20 is a fairly new 20-item questionnaire evaluating various aspects of CIPN. It has three subscales assessing sensory (nine items), motor (eight items), and autonomic (three items) symptoms and functioning with each item measured on an ordinal 1-4 scale (1, not at all; 4, very much). 4 years
Secondary Incidence and severity of other adverse events as assessed by NCI-CTCAE V5.0 Incidence and severity of other adverse events as assessed by NCI-CTCAE V5.0 4 years
Secondary Total pathological complete response (tpCR) rate Total pathological complete response (tpCR) was defined as the absence of invasive lesions in the breast and axillary lymph nodes (ypT0/is ypN0). The tpCR rate is the percentage of participants with tpCR. Within 2 to 4 weeks after completion of neoadjuvant therapy
Secondary Breast pathological complete response (bpCR) rate Breast pathological complete response (bpCR) was defined as no invasive carcinoma in the breast (ypT0/is). The bpCR rate is the percentage of participants with bpCR. Within 2 to 4 weeks after completion of neoadjuvant therapy
Secondary Objective response rate (ORR) The number of participants who achieved complete response and partial response at the end of neoadjuvant chemotherapy as a percentage of the overall evaluable participants. After the last dose to before surgery or within 28 days
Secondary Invasive disease-free survival (IDFS) Invasive disease free survival was defined as the time from enrollment until the date of first occurrence of one of the following events: invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence (including first metastasis), invasive contralateral breast cancer, second primary invasive cancer (nonbreast, not including squamous or basal cell skin cancers, or new in situ carcinomas of any site), or death from any cause. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2